Abstract
Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Current Chemical Biology
Title: Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer
Volume: 3 Issue: 3
Author(s): Ana Maria Inda, Marcela Nilda Garcia, Laura Beatriz Andrini, Adriana Laura Garcia, Ayelen Fernandez Blanco, Cecilia Cristina Furnus, Susana Mercedes Galletti, Javier Brandoni, Jorge Guillermo Martinez, Guillermo Daniel Prat and Ana Lia Errecalde
Affiliation:
Keywords: Colon cancer, VEGF, CD34, angiogenesis, colon, adenocarcinoma
Abstract: Background: The most potent angiogenic factor is the vascular endothelial growth factor (VEGF), and CD34 is an endothelial antigen that has been used to highlight the microvasculature vessel density (MVD) as a direct marker of the degree of neoangiogenesis. In the present study we report that VEGF expression and its relationship with MVD, in poorly and well differentiated colon adenocarcinoma, in order to consider the possibility of using the correlation between both antibodies as a prognostic factor. Materials and Methods: Tumor sections were stained by immunohistochemistry for CD34 and VEGF. Results: The mean of VEGF and CD34 did not show any significant differences between both types of tumors. Conclusion: The conventional factors taken into consideration were not significantly related to the angiogenic factors examined, so we could affirm that the correlation of both markers could be useful as prognostic factor.
Export Options
About this article
Cite this article as:
Inda Maria Ana, Garcia Nilda Marcela, Andrini Beatriz Laura, Garcia Laura Adriana, Blanco Fernandez Ayelen, Furnus Cristina Cecilia, Galletti Mercedes Susana, Brandoni Javier, Martinez Guillermo Jorge, Prat Daniel Guillermo and Errecalde Lia Ana, Evaluation of Angiogenesis with the Expression of VEGF-C and CD34 in Human Colon Cancer, Current Chemical Biology 2009; 3 (3) . https://dx.doi.org/10.2174/2212796810903030302
DOI https://dx.doi.org/10.2174/2212796810903030302 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery IL-13 and its Signal Pathway: Promising Targets in the Development of a Therapeutic Agent for Bronchial Asthma
Current Signal Transduction Therapy Cisplatin and Probiotic Biomass Loaded Pessaries for the Management of Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry The Histone Deacetylase SIRT6: At the Crossroads Between Epigenetics, Metabolism and Disease
Current Topics in Medicinal Chemistry Analysis of Comparative Proteomic and Potent Targets of Peniciketal A in Human Acute Monocytic Leukemia
Anti-Cancer Agents in Medicinal Chemistry Human Immunodeficiency Virus-Induced Apoptosis of Human Breast Cancer Cells Via CXCR4 is Mediated by the Viral Envelope Protein But Does Not Require CD4
Current HIV Research Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Molecular Mechanisms Underlying St. Johns Wort Drug Interactions
Current Drug Metabolism Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets Differential Effects of Antofine N-Oxide on Solid Tumor and Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Lipid Based Nanoparticles as Inherent Reversing Agents of Multidrug Resistance in Cancer
Current Pharmaceutical Design Non-viral Delivery Systems for the Application in p53 Cancer Gene Therapy
Current Medicinal Chemistry Protective Effects of Curcumin against Lipopolysaccharide-Induced Toxicity
Current Medicinal Chemistry Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery